
Dyadic Reports First Quarter 2025 Financial Results and Highlights of Recent Company Progress
Expanded life science and industrial portfolio with six additional life science products in development Advances toward commercialization of functional recombinant solutions for cell culture media, nucleic and industrial enzyme markets Up to $4.5 million …